Satellite Symposium 2020: Focus on Flu with an Eye on Treatment
Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. PAs, NPs, primary care physicians, and other healthcare professionals can identify and help manage influenza in the community. Better diagnostic modalities, more effective treatments, and practical methods to control the spread of influenza are needed. Although diagnostic tests for influenza exist and are currently being utilized, newer modalities are emerging that have promising advantages. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Clinicians who evaluate patients must keep apprised of new information regarding the diagnosis and treatment of influenza so they can incorporate this information into practice, reducing patient morbidity and mortality. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will evaluate approved antiviral agents regarding their novel mechanisms of action and ability to reduce duration of clinical illness and complications. They also will incorporate didactic presentations, a case-based discussion, as well as Game On! to engage learners, thus facilitating better application of information into clinical practice.
Learning ObjectivesAt the conclusion of this activity, participants should be able to:
- Apply new evidence into practice regarding the use of diagnostic testing for patients suspected with flu infection
- Differentiate current options for the treatment of influenza based upon their efficacy and ability to reduce transmission of the disease
- Utilize antiviral agents as needed to treat patients who are at normal or high risk for complications from influenza